Analgesics for Inflammatory Pain

Technology #20130119

More Potent Analgesics for Inflammatory Pain

An analgesic has been synthesized that’s been proven to reduce post-operative pain, neuropathic pain, and pain from burns, spinal injuries and terminal cancers. There was no perceivable tolerance displayed in mouse model in vivo studies, while inflammatory pain was effectively reduced. This synthetic analgesic is more potent than other opioid analgesics due to simultaneous activation of opioid pathways and blockage of hyperalgesia caused by metabotropic glutamate-5 receptor signaling. The analgesic has widespread applications in inflammation reduction and pain treatment.

**MN-IP Try and Buy**

This technology is available via a standard negotiated license agreement. Contact Raj Udupa for specific details.

Limitations of Morphine and Currently Available Pain Killers

Current pain treatments rely upon analgesics such as morphine, which can be habit forming and develop tolerance by the body, requiring increased dosages and extended use in order to be effective. Morphine and synthetic opioids are marginally effective or become ineffective, particularly upon chronic administration, in treating certain spinal injuries, neuropathic pain, burns, inflammation, post-operative pain, and pain caused by terminal cancers. There is a prevalent need for the development of potent, effective analgesics that are able to treat these injuries and illnesses without dependency and tolerance.

**BENEFITS AND FEATURES OF POTENT ANALGESICS FOR INFLAMMATORY PAIN:**

Learn about more groundbreaking discoveries at [www.research.umn.edu/techcomm](http://www.research.umn.edu/techcomm)
- The body does not develop tolerance to the drug, making it a viable alternative to opioids that require increased doses over time
- Able to reduce and inhibit neuropathic pain, post-operative pain, and pain in burns, spinal injuries and inflammation not usually treatable with morphine or other opioids
- Synthetic analgesic is more potent and effective than other opioid analgesics

**Fulfillment Details** Licensee will receive rights to practice the intellectual property (patent application) for the purposes of developing and manufacturing a commercial product.

**Phase of Development** In vivo animal studies

**Inventors**

Philip S. Portoghese, PhD

Distinguished Professor, Medicinal Chemistry, College of Pharmacy

Eyup Akgun, PhD

Research Associate Professor, Medicinal Chemistry, College of Pharmacy

**IP: UM Docket 20130119**

**For additional information, contact**

Raj Udupa  
Technology Licensing Officer  
exprlic@umn.edu  
612-624-3966